Literature DB >> 31463702

Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue.

Chun Hu1, Xiaoyan Wu2.   

Abstract

The prevalence of asymptomatic HUA is increasing year after year. HUA is a risk factor for the occurrence and development of renal diseases. However, the role of urate-lowering therapy in asymptomatic HUA complicated by renal damage is still controversial. In some experiments, the treatment of asymptomatic HUA complicated by renal damage may delay the progression of kidney damage. In addition, there is increasing evidence, suggesting that elevated serum uric acid is an independent risk factor for kidney disease. However, in other studies, uric acid-lowering therapy did not improve renal function, and uric acid levels could not be used as an independent predictor for CKD development. Further experimental studies are needed to determine the starting threshold and target value of asymptomatic HUA complicated by renal damage. At the same time, confirmation of the benefits of urate-lowering therapy for kidneys requires studies with larger samples and high-quality RCTs.

Entities:  

Keywords:  Asymptomatic HUA; Renal damage; Urate-lowering therapy

Mesh:

Year:  2019        PMID: 31463702     DOI: 10.1007/s11255-019-02256-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  55 in total

1.  Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.

Authors:  Yui-Pong Siu; Kay-Tai Leung; Matthew Ka-Hang Tong; Tze-Hoi Kwan
Journal:  Am J Kidney Dis       Date:  2006-01       Impact factor: 8.860

2.  Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.

Authors:  Yumo Zhao; Lubin Xu; Dongli Tian; Peng Xia; Hua Zheng; Li Wang; Limeng Chen
Journal:  Diabetes Obes Metab       Date:  2017-09-27       Impact factor: 6.577

3.  Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.

Authors:  Anand Srivastava; Arnaud D Kaze; Ciaran J McMullan; Tamara Isakova; Sushrut S Waikar
Journal:  Am J Kidney Dis       Date:  2017-11-11       Impact factor: 8.860

Review 4.  Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound.

Authors:  Davide Viggiano; Giuseppe Gigliotti; Gianfranco Vallone; Anna Giammarino; Michelangelo Nigro; Giovambattista Capasso
Journal:  Kidney Blood Press Res       Date:  2018-04-19       Impact factor: 2.687

5.  Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.

Authors:  Marian Goicoechea; Soledad Garcia de Vinuesa; Ursula Verdalles; Eduardo Verde; Nicolas Macias; Alba Santos; Ana Pérez de Jose; Santiago Cedeño; Tania Linares; Jose Luño
Journal:  Am J Kidney Dis       Date:  2015-01-13       Impact factor: 8.860

6.  A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.

Authors:  Mehmet Kanbay; Bulent Huddam; Alper Azak; Yalcin Solak; Gulay Kocak Kadioglu; Ismail Kirbas; Murat Duranay; Adrian Covic; Richard J Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

7.  Uric Acid: The Lower the Better?

Authors:  Gianni Bellomo; Antonio Selvi
Journal:  Contrib Nephrol       Date:  2018-01-23       Impact factor: 1.580

8.  Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.

Authors:  Ralf G Thiele; Naomi Schlesinger
Journal:  Rheumatol Int       Date:  2009-06-20       Impact factor: 2.631

Review 9.  Epidemiology, risk factors, and lifestyle modifications for gout.

Authors:  Kenneth G Saag; Hyon Choi
Journal:  Arthritis Res Ther       Date:  2006-04-12       Impact factor: 5.156

10.  Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis.

Authors:  Kumiko Momoki; Hiroshi Kataoka; Takahito Moriyama; Toshio Mochizuki; Kosaku Nitta
Journal:  J Atheroscler Thromb       Date:  2016-10-26       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.